Exploratory pooled analysis (studies 004 and 006 combined) of a) categorical forced vital capacity change at week 72 and b) 6-min walk test distance decrement.

Slides:

Advertisements

Similar presentations

Pulmonary response in sarcoidosis

Advertisements

Quit rate (7-day point prevalence) for long-term nicotine replacement therapy users in the varenicline and placebo groups from weeks 2 to 52, verified.

Comparison of the characteristics at first enrolment for United Network for Organ Sharing (UNOS) patients (n=8315) and virtual patients (n=2 048 784).

Disease progression is preceded by right ventricular remodelling, but not by changes in clinical parameters. Disease progression is preceded by right ventricular.

High-resolution computed tomography (HRCT) features of interstitial lung abnormalities. a) HRCT of a 56-year-old patient whose mother died of idiopathic.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

In chronic haemorrhage a) several pigmented macrophages fill the alveoli with dense fibrosis of the interstitium; b) the haemosiderin pigment in macrophages.

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

Volume 155, Issue 4, Pages (April 2019)

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

REVEAL pulmonary arterial hypertension (PAH) risk score.

Level of physical activity by Global Initiative for Obstructive Lung Disease (GOLD) stage, BODE (body mass index, FEV1 for airflow obstruction, dyspnoea,

Extent of interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD. A simple stratification that utilises pulmonary function.

Representative diaphragm electromyogram (EMG) tracings at rest (a and b) and during maximum voluntary ventilation (c and d) in a healthy subject (a and.

Sensitivity analysis describing the features of the lymphatic control on pleural liquid volume. Sensitivity analysis describing the features of the lymphatic.

Production of reactive oxygen species.

Schematic representation of the current evidence for the association of cadmium exposure with smoking-related lung disease including chronic obstructive.

Probability of death as a function of the number of months after randomisation in the National Emphysema Treatment Trial comparing medical therapy (––––)

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Reverse remodelling of left and right cavities under specific therapy in a patient with severe idiopathic pulmonary arterial hypertension. a) Before specific.

Prevalence of chronic bronchitis in relation to active smoking, stratified by age. □: nonsmokers; ▒: 1–10 cigarettes per day; ░: 11–20 cigarettes per day;

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Forest plots of the correlation between high-resolution computed tomography (HRCT) scores and pulmonary function test values. Forest plots of the correlation.

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Profile of Pseudomonas aeruginosa resistance by country and antibiotic

Cumulative count of the different primary pulmonary function test (PFT) outcomes in longitudinal studies of systemic sclerosis-associated interstitial.

Time to disease progression or death in a) the whole Bosentan Use in Interstitial Lung Disease (BUILD)-1 study population and b) the subpopulation with.

The projected numbers of tobacco-related deaths between 2000–2035 in millions for a) the world and b) medium- and low-income countries (top) and high-income.

Forest plot comparison of mucolytics versus placebo for the number of exacerbations per patient per month. Forest plot comparison of mucolytics versus.

Post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio in subjects aged >50 yrs. Post-bronchodilator forced expiratory.

a) The Spiration (Spiration, Inc. , Redmond, WA, USA) device

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Effect of omalizumab on change from baseline (B) in a) total asthma symptom score, b) total rhinitis symptom score, and c) combined asthma and rhinitis.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on changes in.

A) Cumulative count and b) percent cumulative use of the different pulmonary function test (PFT) measures as longitudinal outcomes for systemic sclerosis-associated.

Algorithm for the assessment of fitness to fly in chronic obstructive pulmonary disease patients. Algorithm for the assessment of fitness to fly in chronic.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day−1)

A) Measurement of the right atrial a) area and b) long axis for calculation of right atrial volume. c) Measurement of the left ventricular eccentricity.

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

Forest plot of the a) sensitivity and b) specificity of different pulmonary function test screening algorithms for the presence of systemic sclerosis-associated.

Effects of N-acetylcysteine (▒) and placebo (░) on vital capacity (VC) and diffusing capacity of the lung for carbon monoxide (DL,CO) depending on baseline.

Forest plot meta-analysis of the impact of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations on a) St George's.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

The effect of inhaled tiotropium (18 μg once daily) on the improvement in treadmill exercise endurance time in patients with chronic obstructive pulmonary.

Impact of dose adjustment in case of adverse drug reaction (ADR; includes dose interruption and/or reduction). a) No dose adjustment and b) dose adjustment.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Representative pressure tracings of a) pulmonary arterial pressure and b) pulmonary arterial wedge pressure (PAWP). Representative pressure tracings of.

The “route to quit” model, which indicates the contribution of different ways of quitting to overall rates of smoking cessation. #: in most cases nicotine.

Relationship between a) forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and b) forced expiratory flow at 75% of FVC (FEF75%)

Cumulative mortality over 60 months in patients with α1-antitrypsin deficiency and an initial forced expiratory volume in 1 s

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

A) Tidal volume (VT) (presented as % predicted of vital capacity (VC)), b) breathing frequency (Fb), c) dynamic inspiratory capacity (IC) and d) inspiratory.

Effect of omalizumab (n = 209) on a) clinically significant and b) severe exacerbation rates, compared with placebo (n = 210). #: adjustment due to a pre-study.

Reduction in craving expressed as area under the curve during 60 min for a) Nicorette 4 mg gum (♦), mouth spray (▴), lozenge (•) and placebo lozenge (▪);

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Adjusted mean±se response in peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) at week 24, following once-daily tiotropium Respimat.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Progression in the patient’s pulmonary function tests from 2010 to a) Forced vital capacity (FVC); b) total lung capacity (TLC); c) diffusing capacity.

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Trends of mortality rates in the USA between 1930 and 2000 in males according to cancer site. –––––: stomach; ·······: prostate; –– –– ––: colon and rectum;

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

A) Dyspnoea response at rest, iso-time, and peak exercise in 20 patients with fibrotic interstitial lung disease during constant work-rate cycle exercise.

Survival estimates of patients in REVEAL using Kaplan–Meier estimates stratified by newly versus previously diagnosed patients and survival estimated by.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Exploratory pooled analysis (studies 004 and 006 combined) of a) categorical forced vital capacity change at week 72 and b) 6-min walk test distance decrement >50 m (p = 0.03 Cochran–-Haenszel row mean score test based on five categories) [28, 31]. ▒: pirfe... Exploratory pooled analysis (studies 004 and 006 combined) of a) categorical forced vital capacity change at week 72 and b) 6-min walk test distance decrement >50 m (p = 0.03 Cochran–-Haenszel row mean score test based on five categories) [28, 31]. ▒: pirfenidone 2,403 mg·day−1 (n = 345); ░: placebo (n = 347). *: p<0.05; #: p = 0.003; ¶: p≤0.001. U. Costabel Eur Respir Rev 2011;20:201-207 ©2011 by European Respiratory Society